Bai Anthony D, Jiang Yunbo, Nguyen David L, Lo Carson K L, Stefanova Isabella, Guo Kevin, Wang Frank, Zhang Cindy, Sayeau Kyle, Garg Akhil, Loeb Mark
Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.
JAMA Netw Open. 2023 Jan 3;6(1):e2253301. doi: 10.1001/jamanetworkopen.2022.53301.
Randomized clinical trials (RCTs) on COVID-19 are increasingly being posted as preprints before publication in a scientific, peer-reviewed journal.
To assess time to journal publication for COVID-19 RCT preprints and to compare differences between pairs of preprints and corresponding journal articles.
This systematic review used a meta-epidemiologic approach to conduct a literature search using the World Health Organization COVID-19 database and Embase to identify preprints published between January 1 and December 31, 2021. This review included RCTs with human participants and research questions regarding the treatment or prevention of COVID-19. For each preprint, a literature search was done to locate the corresponding journal article. Two independent reviewers read the full text, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2 tool. Time to publication was analyzed using a Cox proportional hazards regression model. Differences between preprint and journal article pairs in terms of outcomes, analyses, results, or conclusions were described. Statistical analysis was performed on October 17, 2022.
This study included 152 preprints. As of October 1, 2022, 119 of 152 preprints (78.3%) had been published in journals. The median time to publication was 186 days (range, 17-407 days). In a multivariable model, larger sample size and low risk of bias were associated with journal publication. With a sample size of less than 200 as the reference, sample sizes of 201 to 1000 and greater than 1000 had hazard ratios (HRs) of 1.23 (95% CI, 0.80-1.91) and 2.19 (95% CI, 1.36-3.53) for publication, respectively. With high risk of bias as the reference, medium-risk articles with some concerns for bias had an HR of 1.77 (95% CI, 1.02-3.09); those with a low risk of bias had an HR of 3.01 (95% CI, 1.71-5.30). Of the 119 published preprints, there were differences in terms of outcomes, analyses, results, or conclusions in 65 studies (54.6%). The main conclusion in the preprint contradicted the conclusion in the journal article for 2 studies (1.7%).
These findings suggest that there is a substantial time lag from preprint posting to journal publication. Preprints with smaller sample sizes and high risk of bias were less likely to be published. Finally, although differences in terms of outcomes, analyses, results, or conclusions were observed for preprint and journal article pairs in most studies, the main conclusion remained consistent for the majority of studies.
关于新型冠状病毒肺炎(COVID-19)的随机临床试验(RCT)在发表于科学、同行评审期刊之前,越来越多地以预印本形式发布。
评估COVID-19 RCT预印本发表在期刊上的时间,并比较预印本与相应期刊文章之间的差异。
本系统评价采用元流行病学方法,利用世界卫生组织COVID-19数据库和Embase进行文献检索,以识别2021年1月1日至12月31日期间发表的预印本。本综述纳入了有人类参与者的RCT以及关于COVID-19治疗或预防的研究问题。对于每篇预印本,进行文献检索以找到相应的期刊文章。两名独立评审员阅读全文、提取数据,并使用Cochrane偏倚风险2工具评估偏倚风险。使用Cox比例风险回归模型分析发表时间。描述了预印本与期刊文章对在结果、分析、结果或结论方面的差异。于2022年10月17日进行统计分析。
本研究纳入了152篇预印本。截至2022年10月1日,152篇预印本中有119篇(78.3%)已发表在期刊上。发表的中位时间为186天(范围为17 - 407天)。在多变量模型中,样本量较大和偏倚风险较低与在期刊上发表相关。以样本量小于200作为参照,样本量为201至1000和大于1000的发表风险比(HR)分别为1.23(95%CI,0.80 - 1.91)和2.19(95%CI,1.36 - 3.53)。以高偏倚风险作为参照,存在一些偏倚担忧的中度风险文章的HR为1.77(95%CI,1.02 - 3.09);偏倚风险低的文章的HR为3.01(95%CI,1.71 - 5.30)。在119篇已发表的预印本中(54.6%),65项研究在结果、分析、结果或结论方面存在差异。在2项研究(1.7%)中,预印本中的主要结论与期刊文章中的结论相矛盾。
这些发现表明,从预印本发布到期刊发表存在相当长的时间滞后。样本量较小且偏倚风险高的预印本发表的可能性较小。最后,尽管在大多数研究中观察到预印本与期刊文章对在结果、分析、结果或结论方面存在差异,但大多数研究的主要结论保持一致。